249 related articles for article (PubMed ID: 32442402)
1. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Yu X; Chan HTC; Fisher H; Penfold CA; Kim J; Inzhelevskaya T; Mockridge CI; French RR; Duriez PJ; Douglas LR; English V; Verbeek JS; White AL; Tews I; Glennie MJ; Cragg MS
Cancer Cell; 2020 Jun; 37(6):850-866.e7. PubMed ID: 32442402
[TBL] [Abstract][Full Text] [Related]
2. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
Liu X; Zhao Y; Shi H; Zhang Y; Yin X; Liu M; Zhang H; He Y; Lu B; Jin T; Li F
Nat Commun; 2019 Sep; 10(1):4206. PubMed ID: 31562320
[TBL] [Abstract][Full Text] [Related]
3. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.
White AL; Chan HT; French RR; Willoughby J; Mockridge CI; Roghanian A; Penfold CA; Booth SG; Dodhy A; Polak ME; Potter EA; Ardern-Jones MR; Verbeek JS; Johnson PW; Al-Shamkhani A; Cragg MS; Beers SA; Glennie MJ
Cancer Cell; 2015 Jan; 27(1):138-48. PubMed ID: 25500122
[TBL] [Abstract][Full Text] [Related]
4. Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Yu X; Chan HTC; Orr CM; Dadas O; Booth SG; Dahal LN; Penfold CA; O'Brien L; Mockridge CI; French RR; Duriez P; Douglas LR; Pearson AR; Cragg MS; Tews I; Glennie MJ; White AL
Cancer Cell; 2018 Apr; 33(4):664-675.e4. PubMed ID: 29576376
[TBL] [Abstract][Full Text] [Related]
5. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
6. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
7. Differences in IgE isotype switching induced by anti-CD40 monoclonal antibody and cytokines among subtypes of chronic B lymphoid leukemias.
Takeuchi H; Kayano H; Hirose T
Exp Hematol; 2000 May; 28(5):543-50. PubMed ID: 10812244
[TBL] [Abstract][Full Text] [Related]
8. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.
Filbert EL; Björck PK; Srivastava MK; Bahjat FR; Yang X
Cancer Immunol Immunother; 2021 Jul; 70(7):1853-1865. PubMed ID: 33392713
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Li F; Ravetch JV
Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
11. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.
Turner JG; Rakhmilevich AL; Burdelya L; Neal Z; Imboden M; Sondel PM; Yu H
J Immunol; 2001 Jan; 166(1):89-94. PubMed ID: 11123280
[TBL] [Abstract][Full Text] [Related]
13. TRAF2 and TRAF3 independently mediate Ig class switching driven by CD40.
Jabara HH; Weng Y; Sannikova T; Geha RS
Int Immunol; 2009 Apr; 21(4):477-88. PubMed ID: 19228877
[TBL] [Abstract][Full Text] [Related]
14. Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism.
Hesen N; Anany M; Freidel A; Baker M; Siegmund D; Zaitseva O; Wajant H; Lang I
Bioengineered; 2024 Dec; 15(1):2302246. PubMed ID: 38214443
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Dahan R; Barnhart BC; Li F; Yamniuk AP; Korman AJ; Ravetch JV
Cancer Cell; 2016 Jun; 29(6):820-831. PubMed ID: 27265505
[TBL] [Abstract][Full Text] [Related]
16. TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.
Yu X; James S; Felce JH; Kellermayer B; Johnston DA; Chan HTC; Penfold CA; Kim J; Inzhelevskaya T; Mockridge CI; Watanabe Y; Crispin M; French RR; Duriez PJ; Douglas LR; Glennie MJ; Cragg MS
Commun Biol; 2021 Jun; 4(1):772. PubMed ID: 34162985
[TBL] [Abstract][Full Text] [Related]
17. Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
Ho SK; Xu Z; Thakur A; Fox M; Tan SS; DiGiammarino E; Zhou L; Sho M; Cairns B; Zhao V; Xiong M; Samayoa J; Forsyth CM; Powers DB; Chao DT; Hollenbaugh D; Alvarez HM; Akamatsu Y
Mol Cancer Ther; 2020 Apr; 19(4):1040-1051. PubMed ID: 31974274
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells: the Janus face of anti-CD40.
de Goër de Herve MG; Durali D; Tran TA; Maigné G; Simonetta F; Leclerc P; Delfraissy JF; Taoufik Y
Blood; 2005 Oct; 106(8):2806-14. PubMed ID: 15994291
[TBL] [Abstract][Full Text] [Related]
19. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
[TBL] [Abstract][Full Text] [Related]
20. Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway.
Niimi M; Shirasugi N; Ikeda Y; Kan S; Takami H; Hamano K
Transplantation; 2001 Nov; 72(9):1556-62. PubMed ID: 11707745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
